stocks, lilly and novo, sort of roll over for other reasons over the last couple weeks. i think it's a function of competition, maybe valuation, but there's some other plays sort of, i don't know, under the -- under the radar screen plays that are out there that we've talked about is m&a going to be a theme here? names like viking, we talked to people at summit all different names. does that make sense in this environment? >> i think so. i mean, it just comes down to the future investment that you would need to make as a pharmaceutical company not already in obesity or without an obesity pipeline i mean, to miss out on this market opportunity, i think, is nearly unforgivable. we're talking about the biggest therapeutic category in all of pharma and bio tech within a couple of years from now, so, i think eventually you'll see it pharma may want to wait for all these different data sets to come out and for the kind of competitive landscape to play out, i mean, how many times are we going to go through datasets that move stocks by 20%, 30%, even the large cap names have mov

w lilly. what are your thoughts?ability it has by building these gigantic factories which costs a fortune. it reminds me of the way intel used to be in the heyday. i remain steadfast on eli lilly for my charitable trust. and i urge you to read some stuff about eli lilly. thank you for the kind comments about my staff. oh, about our staff, because it's not my staff, it's our staff. for once, good news was actually good news. and it was able to send stocks higher in the third quarter, which is proof that miracles can still happen! ♪ hallelujah ♪ >> on "mad" tonight, the fda approved bristol-myers treatment for schizophrenia in adults, and i am learning about the implications of the new class of medicine. it's one we haven't seen in decades. you better listen to this. >>> then, it's a battle of two analysts when it comes to a turnaround at starbucks. >> buy, buy, buy! >> sell, sell, sell! >> i'm laying out the bear case and where i come down. from labels to solar panels so, should investors stick with the stock? i'm che

if eli lilly can be a competitor, this is a crucial time are you make investment decisions.hen prices are high and you have more cash coming in. is that how you view it? lars: yes, to put a bit more color around it, this same forecast predicts that there will be one billion people living with obesity in 3035. we are serving one of 2 million of those today. so there's a huge market in a place for more. and then you are right that in most markets, when you get more competition, and also over time pricing moves down because you start treating those who accept the higher price point, in the u.s. its commercial insurance, and then you get broader access and you get your patients paying a lower price. if you just take our leading diabetes product in the u.s. since it launched in 2018, the price we get after we face discount is some 40% lower than will be launched. that's often not mentioned in the political debate, instead, this price is mentioned, which is not what we booked in our account because it's after rebate. francine: the u.s. is such a large market, would you do a list o

into pfizer is one. >> oh, lilly into your pfizer, karen. >> well, i have lilly, too, but my pfizer, yes. i know, that would be good. it's been a long time waiting for pfizer to be from ridiculously cheap and a nice yield to something better than that. >>> coming up, shares of intel getting a bump again today on news of potential big investment. will it enough to help them launch a real turnaround? >>> plus, wall street weighing in on gm and nike, but analysts aren't loving what they're seeing under the hood or in the sole. don't go anywhere. "fast money" is back in two. >>> this is "fast money" with melissa lee right here on cnbc. t keep this world turning. it's the go-tos that keep us going. the places we cheer. trust. hang out. and check in. they all choose the advanced network solutions and round the clock partnership from comcast business. powering more businesses than anyone. powering possibilities. ♪ring jingle♪ -whasssssup. -greetings happen. yeah, that's not good happens. huge things happen. home happens. -woo hoo! -be there with ring. learn more at ring.com. (♪♪) car, this

we know of eli lilly. we know amgen could be a competitor.nd so this is, i guess, the crucial time when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 2030, 2035. we are perhaps serving one million or two million of those today. so, there is a huge market opportunity, and there is a place for more. and then, you're right, that in most markets when you get more competition, and also over time, pricing moves down, because you start treating those who accept, say, the higher price point -- in the u.s., that's commercial insurance -- and then, over time, you get broader access, and you get patients paying a lower price. so if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc. is some 40% lower than when we launched. that's often not mentioned in, say, the political deb

. >> they could but the best thing are the stocks, they keep going up and up, eli lilly is up 700 ander the past five years and is partially because the obesity drugs are all that matter they start off as diabetes drugs and now they turn out to help lose weight but they do all kind of other things to. lily came out with data showed that it might prevent type two diabetes but is also been shown to help with sleep apnea, heart failure, addiction, all summers and i'm waiting for it to come out to bring world peace. that would be great, they are fantastic. jack: that said there is a norm is revenue potential but in order to get revenue 70 has to spend money and it's not clear who's going to pay the very high price of the drugs. >> are trying to come up with new ways to do this. eli lilly came out with a new way a discount version of that bound which is complicated to use but it brings the price down but they're very expensive especially for weight loss and you see a lot of the insurers do not want to pay for it. we have a reporter talk to a hospital ministry or the said there's 40% of pat

lilly is going to do what lilly does. but you have to be careful with respect to owning too much health care. >> isn't it a looming positive that eventually these drugs are going to get government reimbursement approved, in which case you have 8%, 9%, 10% of the population on them, especially when every day we hear there's always a new malady. >> i think there are going to be a few winners, not across the entire sector. we're betting on the entire sector to be like that. >> what about the u.s. versus other areas? we're talking more about china more than years, at least in a positive day. you could look at a number of the tech names are doing quite well. is now the moment, even though the stocks are up a lot since the stimulus announcement? >> we've never been believers in the china market. it's massively underperformed for ten years. whether or not this is the bottom, they've had a d-shaped recovery. obviously with the stimulus. remember, too, from a secular basis, we have to teach that population how to spend money. the

if you look at the fundamentals of this company, you know, it's much cheaper than lilly, but lilly seems. this is a company if they don't have the ability to move towards oral they might have to vertically integrate a little bit and focus on getting the supplies of the shot. right now we know that there's issues as it relates to the pens maybe more than the drugs. you know, this is a tough one but looking to play the names there are not that many names unless you're going to be speculative. >> i would agree on the m&a that guy mentioned here. the more that you're getting the pills are really -- that's what everybody wants as opposed to the injections. there's a demand and marketplace for that. if they're not able to have the efficacy they hope to have you see the smaller players have it and you will see more m&a activity in the space. >> a note novo does have another oral candidate which had very good results just last week i think. >>> coming up, constellation energy goes nuclear inside plans to reopen the three mile island the site of america's worst nuclear accident. the details after

i asked eel junior lilly, he's a electra on global affairs and emerging technologies at the u. c. de clinton, the institute for american studies in dublin. so the, the most plausible explanation so far, and the most popular seems to be that of a supply chain of ration that is the page here's where tempered waste, during the manufacturer, or in transit to hezbollah. to make damage the page. here's might have been packed with small amounts of explosive and then figured by remote signal. although possible is important to remember that so far there is no definitely, definitely the answer to how this coordinated attack took place as a pain other examples as we search for a concrete answer and wait for that. had they been other examples before. this of similar sophisticated, the tax and single tiniest attacks like this in the past. i think it's fair to say that this was unprecedented, especially in terms of the context in which it took place. and in the fact that we resulted in a single, in serious and as we saw in some, uh that to however, that said, am operations relying on time pe

why isn't lilly there? >> reporter: that's a great question. of people know the name ozempic, it's really the drug people know. but whether we'll see lilly up here one day, maybe at this point, but it is novo on their own right now. >> speaking of the drugs themselves, we talk to you about this a lot, the oral formulation under way, is there as well the possibility they'll try to figure out one that doesn't -- that reduces weight without actually reducing muscle mass? >> reporter: yeah, that's been in development. it was interesting in the written testimony that the novo nordisk ceo provided ahead of time. he talked about competition and eli lilly and all these other drugs in development and that the natural competition out in the marketplace could bring the cost down over time. saying, look, there's -- these prices are going to go down on their own. you don't need to do anything to bring them down. >> thank you very much. keep us posted outside that senate hearing where the ceo of novo nordisk is testifying as we speak. >>> watching u.s. steel

eli lilly, it's $932 the 2. 9222. >> you know, i don't buy big pharma, and elle tell you why, ashley, it's so hard to get an edge. i try to the find companies where i think i can help my subscribers double, maybe triple their money over two, three, four years, but it's like buying exxon. big, chunky, high cash flow company, but it's hard to get an edge. ashley: yep, very good. let's talk about some changes, big changes at moderna, lauren. what are they up to? lauren: they're slashing their r&d spending over the next four years by 20%. they're also going to pause if not end some drug development entirely. the stock is cratering 15. they need to safe money $15%. -- 15%. they've lost a fifth of their value this year. they had so much of their portfolio locked in on the covid vaccine. that's just not as popular anymore, so they started investing in other drugs and vaccines, and now they're kitting baa investment in -- cutting that investment to save money. ashley: all right. we know what adam feels about these stock

we're seeing between lilly and novo the depth of their pipeline is continuing to evolve.se 1 to phase 3 trials that will only enhance what they're already able to do. whether on the side effect profile, the duration of effect, or to your point on the cost one of the most important features of this is there are a multitude of ways costs will come down for the system it's not only in the shape of competitors that come into the market you're dealing with a do you o - do duopoly. >> we don't think the best money has been made in a novos or lillys >> not necessarily i think we'll be looking at specific drug outcome trials whether or not these drugs continue to impact the long-term effect of patients' health we've seen it in specific studies and the continuation of those studies and the depth of those responses is going to be something that can continue to lift these companies and maintain the earnings potential. >> last time you were here we talked about the prospect for rate cuts and how beneficial that would be to some of the smaller biotech companies that rely on borrowing

eli lilly. first of all, thank you for the comments. eli lilly will be the next trillion dollar company. i think it is remarkable. we did trim some this week because i felt so greedy. we might be able to buy some if it comes down. >> ian in north carolina. >>caller: how are we feeling about your birthday tomorrow? >> we go down to brazil he said they are on the plane, they are on the plane. i like it. it is so nbc and on peacock. there you go. i play for us. what is going on? >> listen i am personally bullish on the long-term trend around rare earth materials, am i on the right track with mp materials? >> they are now a show me story. i have been backing them for a long time. i will not back a company that has not been able to capitalize on what is a absolutely important, incredibly good position and they are not making money. that is why the stock is down 30% for the year. >>> okay, we have a ton of stocks rallying right now. it is not, it is health care, finance, utilities, come on. we are getting brooder leadership. we are getting ra

eli lilly, we know that people like that. enough in the name. apple, own it, don't trade it. caterpillar, i thought he said such great things about the data center and all of the different activity. infrastructure. makes me feel terrific about it. costco had a great month. they sold it anyway, but the numbers were better than expected. which brings me to nvidia. here's the problem. apple and nvidia are two of my absolute favorite companies. agency stocks, i said companies. my take away thinking is do we make an exception in this particular case for having this much tech? the answer is no, not in a five stock portfolio. in 10, yes, but in five we have to accept that this is not diversified. you have two understand that that is not diversified because we have a drug company, a retailer, a machinery company and no diversification, but i understand and i hope you have others to dilute that, because it is too much tech for a five stock portfolio. that said to fill in north carolina. >> hey, jim, how are you doing today? >> i am do

i think the valuations give you confidence. >> i think people got so used to rushing in to lilly andmain names for glp-1s. but you look at bristols, people say, i missed the boat on that, let me roll up here, because bristol was $80 a year ago. whatever the number was. it is falling off the cliff. but to julie's point, people are waiting for an oral version of glps. maybe the side effects have pushed people off. maybe they go back to the gib. >> you are, obviously. >> thank you, tim. >> more "fast money" to come. very awkward. here's what's coming up next. >> tesla is putting pedal to the metal this week and wracking up electric gains. with pivotal delivery numbers and hotly anticipated taxi reveal in the headlights, can they keep this going? a clean energy name putting up powerful gains. why one top analyst is betting on ge vernova. you're watching "fast money" live from the nasdaq market site in times square. we're back after this. in 7 days, to imt with significant improvement over time. ( ♪♪ ) *doorbell ring* trick or treat. happy halloween! *zombie grunt* *dog bark* *woman screa

you've got sanofi down 1%, novo nordisk down 5.7% and eli lilly up about 1.25%.usiness, shares of us homebuilder lennar are on sale the stock is getting nailed down even after reporting a third quarter earnings beat. what's to blame for the drop? lennar forecast weaker-than-expected gross margins for the fourth quarter related to buyer incentives. so when you incentivize people to buy, and incentive them by cutting price, your margins go down. the ceo does remain confident a stronger more broad-based demand cycle is ahead. lennar down 5 and one-third percent. fair to say high end home and furniture office and furniture maker hopes so too, and herman miller office chairs among its brands blaming a weak housing market for its disappointing results. the company swung to a loss in the fiscal first quarter, missed on revenue, and provided weak second quarter guidance. on a bright note, their recent investments in operational capabilities are driving significant margin improvements. still, investors are fleeing the stock it's down about 13.6%. sellers are also chipping

stuart: you brought some stocks along with you that you particularly like i have my eye on eli lillyted with the company is up 1% today, apart from weight loss drugs what's so good about it. >> if you take a step back this is a stock that's been outperforming for many, many months and versus some of the competitors and does more than the weight loss drug and if you look at the health of the financials in a couple quarters of a row of double digit growth that's been accelerating and with the rollout of the weight loss drugs in the early stages, maybe there's a debate about the effectiveness or the health, pros and cons you have to weigh this. stuart: we were having a debate whether i should get we go be or not. >> now, you do not need it you look fit and great. stuart: moving on, eli lilly $912 a share, where you see it going. >> is at a critical level 900 his psychological number in the 50 day moving average, a lot of technical traders will use that and it's finding support i would want to see a nice close today yet to be careful around this level if you want to treat it the 50 day m

i'm actually surprised eli lilly is not trading higher right now because doctors are being warned bynot to supply ozempic or wegovy when hay don't have to because it's in short supply. there's no shortage for eli lilly's weight loss drugs right now, so i thought we would see them the up, but they're downed the today. stuart: do you have any if comment on wonder drugs? >> in fairness, it's up 40% -- 1400% already so i think it's already priced in. where are -- where were they during covid to city i obesity at a large was one of the problems with covid? they never if talked about that as the leading co-morbidity which it was. it creates all kinds of health benefits. stuart: that's the secret, isn't it? it helps all kinds of conditions if you lose significant weigh. >> who could have ever guessedded that? [laughter] stuart: doc siegel's going to be discussing this later in the show. you brought a couple of dividend picks. clorox, you've been there before. >> speaking of during the covid era, remember the wipes? everyone was trying to get ahold of clorox. it's a good dividend grower, up

so bristol myers-squibb, and eli lilly have spent money to get drugs that deliver radiation directlythat big pharma is piling into the space because these drugs contain radioactive material. so making and distributing them isn't easy. they're good for only a few days, and only specialists can handle them. novartis is proving it's possible even if it means for legwork. one doctor saying it's manageable to treat patient? a different way. another saying it's easiest to plan for treatments every six weeks. the only thing he worry bu busbusiness -- worries is a snowstorm in new york. it treats tumors and the opportunity is bringing the willing to to many more cancers like lung and breast. if that pants out revenue could be in the tens of billions. it will take time to see if that work out, but executives say this as becoming an important part of cancer care. it's one to watch. >> this is a deceptively simple question, but how does the drug know where to go? >> it's a good question, and that's because there is markers that we're looking for. for example, psma, that's one that's expressed b

what just happened with summit specifically, but then think about the glp-1 and the head start that lilly novo has. it's going to force mefrck's hand i think at $114, it's cheap, with all the headwinds, this is a stock that i think you buy here, not sell. >>> all right, coming up, roche shares slimming down after disappointing obesity drug data. the struggles, the side effects, and the next steps for the pharma giant that's next. >>> plus, the holiday shopping season is nearly upon us seriously. but analysts are expecting nothing but coal in retailers' stockings this year. the chilly forecast -- >> oh, boy >> next. >> come on, mel. >> oh, boy >>> missed a moment of "fast?" catch us any time on the go. follow the "fast money" podcast. we're back right after this. this is not a drill. subway dropped the price on all their subs. 20% off any sub, any size. subway did what?! any sub? yup! for a limited time. get 20% off when you order in app. hurry and get this deal before it's gone! ge- today, 9 million kids orderin america are considered food insecure, meaning there may not be a lot of dinne

i still like lilly which is why we still tone for the charitable trust.st of keeping things fresh let me give you a new idea. hca health care. that's the big hospital chain. hca's been making a mint in the major uptick in patients coming in for non-urgent procedures. incredibly do you know there's still a huge backlog of people who postponed going to the hospital doorg the pan pandemic? hca reminds me of detroit lions tight end sam laporta, the first international pick of the skee-daddies, my fantasy team in tuesday night's draft. yes i was on autopilot for the first one. laporta burst on the scene with an incredible rookie campaign last year, nearly 00 yards and a whopping ten touchdowns. no other tight end had more than six. wow. that's how he ended up as the tight end last season even outperforming taylor smith's boyfriend. [ rimshot ] but both laporta and hca still somehow feel very undervalued. despite hca being up 47% year to date it still sells for less than 18 times price to earnings. haporta isn't a household name despite a huge first season. two

. >> i'm robert lilly, i'm from wickenburg, arizona.ave a -- i typically do not decide for sure i'm not 100% , until election time. >> my name is anna and i live in the suburb of phoenix, arizona. before the debate, i was already against trump. that's not i don't trust either them as happening. commander in chief or even as necessarily head of government. >> i would say that neither lived up to my expectations. one of the things that i had difficulty with throughout the entire debate was the lack of specifics. >> it seems like a race to the bottom, more than anything. it's not about anybody having any sort of real ideology and the concerns of the majority of the american people that at heart it felt very much about , just being better than your competitor. >> she went in for the handshake. it actually meant something to me. i think civility is going to be the number one thing. we have to get back to that before we can get back to anything else. >> what was interesting and not surprising from donald trump was how easily he was baited int

one of them among big cap is amgen which can be the number three player in the diet drug marker eli lillynobled nordisk, the avenue drug and clinical trials that can have an advantage of being delivered once every two months weekly which is how the current injectables work in the biotech company by entech which is best known as beta covid play but an interesting cancer portfolio is a huge amount of cash on the balance sheet and finally a mentioned revolution medicines which is developing the drug and clinical trials that could treat pancreatic cancer with the huge unmet need given the high mortality rate from that disease. >> we talked about how falling interest rates can help the sector receive that play out against. falling rates are often tailwind for healthcare were seeing that play out tell me about one company they came up with the roundtable illumina, ruf and it's a leading gene sequence and 75%, growth may finally start to accelerate, stocks around 120, 130 could hit 200. in healthcare and drugs and often pays to stick with a good manager because of the wide disparity and returns

eli lilly telling me that you go into a weight loss manufacturing facility and you see a lot more.y but it is still a really complicated production. >> the general take is a lot is about thematic discipline, the way lilly stuck with diabetes for 30 years and wound up with this pressure. is novartis the equivalent on this cancer front? >> exactly. this is something they've been working on for decades. some of the first drugs were approved in the early 2000s, but they weren't that successful and so it was -- there is skepticism whether it was a worthwhile endeavor. now novartis has proven you can make it work. >> what are the cancers that are sort of front lined in terms of this therapy? >> pluvcta for prostate cancer and endokrin cancers. they have proven these are cancers where it's works, but they're also looking at more common cancers like lung, breast cancer, even pancreatic cancer. if it works, there could be a lot more. novartis, they're working on one marker found across 28 different types of cancers. if they can succeed there, it could be a big opportunity. >> how much is de

and lilly is a beautiful girl, she has the first photo shoot was supposed to take place, what photo shoot? well, i don't know where, and she said that it was for a photo calendar, like, either myths of ancient greece or rome, she was supposed to portray cupid there, who? cupid, pasha, the photographer, uh-huh, who conducted spokoynaya's photo shoot, uh-huh, they haven't found it yet, uh-huh, yeah, time flies. it's going, it's going, georgyevich, it's going fast, but wait, what about her boyfriends, the ironclad alibi, georgyevich, yeah, it's lying in the traumatology department, well, okay, okay, okay, let's get to the most enjoyable moment, for the sake of which we have gathered here today, albeit a little late, but with all our hearts we congratulate our charming employee ekaterina latina on her birthday. comrade officers, you come home from work, go to bed, count sheep, but still can't sleep, and every operative wants to know lapina, what kind of bird are you, congratulations, congratulations, a wonderful poem, congratulations, thank you, of course, my birthday was already a weekend, i

the move should act as a deterrent for nato states. waging a proxy war against russia. towards miss lilly, as happened today was the status of the addition of the fund government. those and the shift and vision thinking to balls a debt that ends in the minds of the west maple and in particular the united states of america. it is basically the best buy thing that i sense. so what i show saying here that if you cross the threshold on these lines, we will use the nuclear weapon. i mean somebody can take you to the data, then somebody can try to get us in patients. but i think that doesn't quite fall on what they're thinking about occlusal technical, new nuclear weapons. any good country which has to have to do is go down to the damage with tank on the lines of technically to defense will be a decadent and to stop a water if it is going to continue. so i think that i, since i have that, but i will do it and i think the rest so not that good. so very likely does because the proxy, what is going to be new to the commission items. and then before the caution, it is also going to be noted because

last month, eli lilly announced it would make its drug zepbound more accessible by reducing the loweste to less than $400 a month. that's about what ready pace for her compounded drug now, and she says she is sticking with it after losing more than 50 pounds. what is the feeling that you have now? >> it just feels like a relief. i think it's a miracle drug. i really do. >> that was nancy chen reporting. stay with us. "cbs news roundup" will be right "cbs news roundup" will be right back. wounded warrior project empowers post-9/11 veterans and their families with life-changing programs and services. i realized i could be successful in a civilian career. we stand by warriors and advocate for their needs going forward. they were by my side in the hospital, and they're still with me today. through our programs, community and advocacy, we're proving anything is possible. learn more at wounded warriorproject.org/connect [coughs] when caroline has a cough, she takes robitussin. so, she can have those one on ones again. hey jim! can we talk about casual fridays? oh sure. what's up? get fast, p

to sell because of expect half of doctors to recommend fewer sleep apnea machines because of eli lilly'st loss drugs because they can have sleep apnea. the fda's approval is bad, for the market. stuart: some workers of the new york times are threatening to strike on election day. there's a long list of demands including a 4-day work week. a ban on centered product in break rooms. right now, holding hearing our national security threats on the southern border. looking at the financial and human cost of biden's border crisis. we really don't want people to think of feeding food like ours is spoiling their dogs. good, real food is simple. it looks like food, it smells like food, it's what dogs are supposed to be eating. no living being should ever eat processed food for every single meal of their life. it's amazing to me how many people write in about their dogs changing for the better. the farmer's dog is just our way to help people take care of them. ♪ (luke) homes-dot-com is a new, elevated home-shopping experience. beautiful design, tremendously rich content, and, my favorite touch, it'

. >> reporter: 20-year-old lilly and 22-year-old elliott worry about abortion access and worry aboutefinitely worried about like abortion access. i'm not very well equipped to have kids right now. and so i think that there are a lot of women that, like, in the offchance that, you know, i get pregnant for whatever reason, i want to make sure have i safe access to get a procedure like that done. >> in my family as well, there have been some differences in political opinions, and that's driven us apart. >> reporter: wow. >> i wish it didn't have to be that way. i wish we didn't have to play teams like red team v sus blue >>> it's thursday, september 26th, 2024. this is "cbs news mornings."

lillie just able to immediate backlog orders second quarter but no dtc advertising.oses on limited supply. supply increases, as drug price negotiation comes to light and also as new products make it to market, there are a lot. a huge line behind novo and lilly we'll see affordability and access increase for consumers. >> everybody's going to look after their own self-interests. pbms. many times i think that drug companies might provide a product that's the best value in town for chronic illnesses and that we need to embrace the innovation. are there some bad actors that try to extend patent protection by an extended release version? or, i saw lina khan the other day talk about certain delivery mechanisms for these drugs you can patent one of those small part of something to extend patent production. is there egregious examples of what these drug companies actually are doing? because i tend to come down on their side most of the time. >> a great question. i think historically there has been. but the drug system has changed a lot. we've really moved towards value-based

we like eli lilly. it's been one of the top gainers for all the obvious reasons. they're a leader. we also like warren buffett. last week he celebrated miss 94th birthday and joined the trillion-dollar club. broadening out of the market, we've seen health care. you're going to see that play out. in the magnificent 7, we like microsoft as well. >> robert shein of blanke shein. you can go to cnbc.com for more insight. >>> now let's get a check on the top stories. silvana henao is here with those. good morning. >> sam altman plans to rally investors around building ai infrastructure, apparently moving closer to re. a bloomberg reporting altman is focusing on the u.s. leg of his efforts with a new price tag, totaling tens of billions of dollars. that report adding altman has suspect the first half of the year seeking the u.s. government's approval for a massive data center power plant and chip factory build-out. >>> meanwhile nippon steel is offering an olive branch to buy uss steal including vice president harris, rallying over the weekend saying uss steel should remain operating. we

everyone knows about nvidia and the eli lilly but use peripheral vision to identify other winners ands in those key themes. just taking glp number ones as an example there will be winners and losers. you look at mcdonald's or pepsi, they are all hurting and they used inflation as the scapegoat but the real thing that will impact long-term are these glp number ones. you need to be able to see the forest for the trees. stuart: the russell 2000. and index. >> not now. once it becomes clear that the fed is close to finishing their rate cutting cycle land or the economy has bottomed if it actually is trending downwards, that's when you hop into small caps, small caps underperform following the first rate cut. stuart: you never jumped on the big rally bandwagon. >> i have not. the question i am getting from clients is not can this melt up the 6,000 mark? what about 7,000? they are not asking me that. my clients are saying what if? there's so much uncertainty with the election, fed policy, the economy. my clients are more concerned by year end that we protect the downside. stuart: stay there

correct there introducing for the first time and never powered sleep assist and offer a 3% gain in eli lilly which those weight loss drugs help with sweet untreated sleep apnea to. >> deep answer to walt's face-off tomorrow night and the only vice presidential debate could be the final debate of the election season, alexis mcadams and walt is nervous that's what were hearing from a few sources with debate prep we wonder why he would be a little bit nervous one of the reasons he could be quite of a lot of the debate prep not only that but what on one with other people in his team first and hammer home of immigration and more and this is what the trump team had to say, watch. >> and all the way dating back to the district attorney for san francisco and jd on the terrible decisions that they made throughout her entire career in ten walt has to grapple with trying to explain why kamala harris is not responsible for the crises of the last four years. >> tom emmer has been helping with debate prep role-playing walt's for advanced he's like gavin newsom wearing a flannel shirt what is walt going to

. >> todd: she can try to guild the lilly by saying increase finances on middle class, numbers say oppositeia, i'll be joining you. >> cheryl: see you soon. >> todd: it is a battleground bl blitz, vice president will rally in north carolina and donald trump visits arizona are. quinnipiac poll shows trump lea leading -- by 5 points in arizona. here to react is laurie buckow and sheriff lamb. this question comes from a viewer who is my mom. she says, why would anyone, anyone in arizona vote for kamala harris when it is her reign as border czar that led to the migrant cries, migrant chaos in arizona? >> well, todd, your mom has best question of the day, i don't know how anybody, not just arizona, anybody vote for kamala harris? i think two biggest issues are border and economy. they have failed the american people miserably when it comes to both issues. the border is out of control, we're seeing more and more americans become victims of crime and more and more cities having trouble with not just criminals, but fentanyl poisoning. the list goes on and on, i don't understand how 50% of americans

and because eli lilly was there looking for protections for u.s. companies operating in india.big news with intel today. did he have any comments about that? >> reporter: yeah, huge news. that was when that broke on friday, that was blockbuster. i asked huang about that. he is largely to credit for what we have seen at intel and the downfall in recent years catching up to the a.i. moment. he told me he wouldn't be too concerned if those two companies did end up merging because he's really focused on what nvidia is doing. they control that entire technology stack. that means not just the chips that nvidia makes, but the software and firmware that power the chips. he ses that as a real competitive advantage nvidia has over intel and qualcomm. >> steve kovach, thank you very much. good to see you. >>> coming up here on "worldwide exchange," the energy play our next guest says is high on her shopping list and why it could add to the already 15% jump isth year. if you haven't already, follow our podcast on apple or spotify or other podcast apps. much more "worldwide exchange" coming

{lilli with staff struggling to work in 19th-century buildings.need is this _ 19th-century buildings. our most urgent need is this site, - 19th-century buildings. our most urgent need is this site, we i 19th-century buildings. our most urgent need is this site, we need j 19th-century buildings. our most i urgent need is this site, we need a complete rebuild of the hospital. there is new technology, like this robot in the hospital pharmacy, but staff say things would work much more efficiently in a modern workplace. hugh pym, bbc news. i'm joined by our political correspondentjoe pike and how social affairs editor alison holt. this wasn't part of the remit? lard this wasn't part of the remit? lord dardai says — this wasn't part of the remit? lord dardai says a _ this wasn't part of the remit? lfr'c dardai says a functioning social care system is vital to the nhs particularly if services shift from hospitals into the community. the problems in social care are well known. staff shortages, underfunding for years and known. staff shortages, underfundin

. >> i'm katie bo lillis in washington cnn tonight, the son of the late senator john mccain says donald trump's campaign event at arlington national cemetery was a violation with first lieutenant jim mccain telling jake tapper this earlier these young people are taking time out of their lives when they could be bettering themselves, college, things like that and they're joining the military because they feel it's the right thing. >> and the least we can do is when they're gone, if they when they're in arlington is to respect the rules and regulations that are in place, like not politicizing the fact that these men and women are there go show respect under i understand that he was invited. show respecting leaf. it doesn't need to be videoed that comes as trump is continuing to insist that the u.s. army is lying about what happened during that visit was no conflict, there was no fight. it was no anything. and i get home that night and i get a call from one of the people that is press sir, there's a story that your people got into a tremendous fight with people representing the cemetery tr

it had a good week. >> lilly is down about 3%. the year's winners. >> yeah. >> the rotation that you talk about, mike, how do you -- is there a way to understand whether it's sustainable in some fashion? >> yeah, i mean -- >> what do you look at to sort of try to see? >> i think that's the current obsession. just this kind of, like, okay, you know, the pendulum swings a little bit, you give the nasdaq 100 three months to cool off and maybe it resumes. yesterday there were signs semis wanted to grab the lead again. i think one of the issues the market will have in general is there's a little less open-ended. you kind of already have a 17, 18 times forward multiple on the non-mag seven stocks. it's not like they're super cheap, and i think it's one of those issues. goldman-sachs today, tony pasquariello note talking about what the s&p multiple was in the first fed rate cut in prior soft landings, and we're, like, way above. you were, like, 15-ish, 14-ish, 11, maybe 17 if you widogo back let's say, 2017, 2018, 2019. you've already ma

. >>> news out of cignet, kroger, lilly and more trying to build on yteesrday's reversal "squawk on thetreet" is back in a moment. tax smart investing today, helps to build a stronger tomorrow. at pgim custom harvest, our unique direct indexing approach seeks to help investors achieve better after-tax outcomes. pgim investments. shaping tomorrow, today i can't believe you corporate types are still calling each other rock stars. you're a rock star. we're all rock stars. oooo look look at my data driven insights, i'm a rock star. great job putting finance and hr on one platform with workday. thank you! guys, can you keep it down. i'm working. you people are (guitar noises). hand over the air guitar. i've got another one. >>> railroad operator norfolk southern ousting alan shaw, out as ceo he's been replaced by cfo mark george investigation determined shaw violated company policies by engaging in a consensual relationship with the company's chief legal officer. jim, shares down about 1% premarket. >> they put in someone who is a non-operator at norfolk southern they didn't know this was co

and it looks like eli lilly has nothing similar and they since competition. and there is has gone down a 40% to 50%. and that is what we need more of. until you put it out there, expose the pbms in terms of what they are getting, and you get consumers engaged in it, you are not going to solve the problem. are going to end up having government as your business partner. because when you operate like an unregulated utility, you're going to get government regulating you. and i think there's a strong interest in that happening. unless you, hospitals, insurance, take the bull by the horns you're going to increasingly be more conversations like this. i want to end on this, so, why should the europeans and everyone else be taking advantage of the fact that we do the r&d. why don't you charge them more so where there is at least not eight 10 to one differential to where you share the cost across the world, not put it on the burden of the place that is now borrowing $.30 of every dollar for whatever is provided to government, and to where you are jabbing it into privat

and the restraint in the index, i was just looking, the downside pressure coming from lilly, microsoft. year-to-date winners kind of harvested to be put elsewhere. i think it's okay. positioning seems full. it looks like we're going to sidestep the ugly september headwind. only two more trading days to go. >> barring a surprise warning from pce. we're still waiting for that. it may carry a little less importance because we've moved beyond it. but it still matters. >> i think you still want to be able to check it off. you want to make sure it's still in line with the trend and i think more to the point, the market has itself priced for benign inflation environment, friendly fed and supportive growth picture. all that's great, but you have to have it confirmed along the way. >> china stuff is pretty dramatic if you look at all the companies, a swath of estee, lvmh, wynn, sands, freeport. pick your sector. >> the communist party of china is pretty good at trading this market because it was really washed out and everybody leaning towards uninvestable. it remains to be seen if this grows in

constellation energy, all right, nike, super micro computer and eli lilly back on that list.daq winner, crowdstrike, siriusxm, doordash and exelon corms. the 10-year treasure -- corpse. 3-- corporation. 3.75% right now. the price of gold, if that's not a record, it's close, $2, 633 per if ounce. bitcoin moving to $62,800. the price of oil, that's around $71, 72 a barrel. not much change, $71.58. and nat gas, $2.33. the average price for a regular gallon of gasoline is $3.22, no change overnight. and in in the california, or yes, it is $4.75 for regular. >>> coming up, hezbollah leaders call coordinated pager blasts a deck la rakes of war. -- declaration of war. where does this leave ceasefire and hostage release negotiations? we'll ask christian whiton to. harry and harry and meghan agerring people to vote. megyn: meghan is queen woke and has to keep her place among the woke heats of hollywood. that is my take, and it's at 10:00 -- sorry, 11:00. steve hilton will be here shortly. could blue collar workers be the key to turning new york red for trump? a new york union leader p